EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — Trials · CancerIndex

Clinical trials

Registered studies

20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 13
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07097363	Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma	recruiting	Phase 2	18	University of WashingtonOTHER	1	Apr 23, 2026	clinicaltrials
NCT05934448	Pembro Plus CAR T-cell Therapy in R/R in PMBCL	recruiting	Phase 2	35	Jennifer Crombie, MDOTHER	1	Mar 5, 2026	clinicaltrials